Nov 18 Ablynx NV :

* Clinical pipeline further advanced with one phase III andfour phase II studies currently on-going in-house, and firstpotential product launch in 2018

* Positive outlook for next 12 months with a number ofimportant milestones

* 9-month revenues up 52 pct to 53.6 million euros ($57.1million) (2014: 35.2 million euros)

* 9-month operating loss of 13.3 million euros (2014: lossof 11.7 million euros)

* 9-month net cash inflow of 56.0 million euros (2014: 21.1million euros)

* 9-month cash position of 262.2 million euros (2014: 221.5million euros)

* Expects to publish results from the first-in-infant phaseIIa study with the anti-RSV nanobody, ALX-0171, in the firsthalf of 2016

* Results from the two phase IIb RA studies with theanti-IL-6R nanobody, ALX-0061, are expected in the second halfof 2016

* Company expects its net cash burn for the full year 2015to be at the lower end of the previously guided range of 70-80million euros

Source text for Eikon: Further company coverage: ($1 = 0.9392 euros) (Gdynia Newsroom)